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SUMMARY
High cell viability and recovered cell concentration are typical quality control re-
quirements for single-cell processing and quality data. This protocol describes
procedures for sampling, live-cell biobanking, preprocessing for single-cell
RNA sequencing, and analysis of fine-needle aspiration (FNA) samples of the
skin. The minimally invasive nature of FNA collection is more accepted by pa-
tients and allows for frequent longitudinal sampling, resulting in high-quality sin-
gle-cell sequencing data that capture cellular heterogeneity in clinical samples.
BEFORE YOU BEGIN
The protocol below outlines preparation steps for fine needle aspirate collection (FNA) and its pre-
processing for single cell RNA sequencing on cutaneous cancer lesions. We have performed the
FNA sampling on cutaneous B cell lymphoma and cutaneous melanoma metastases.
Preparation for FNA procedure and biobanking of clinical samples
Timing: 20 min
1. Prepare the syringe holder (e.g., Pistomed, MED1000522, medesign, Dietramszell - Linden, Ger-
many) suiting syringe (e.g., 20 mL) and needle (e.g., G23)
2. Prepare disinfecting wipes and a bandage
3. Prepare a 1 mL cryovial with slow freezing medium (FBS 90%, DMSO 10%) and place it on ice
4. Pre-cool the cryo container (CoolCell LX, BioCision, BCS-405G, Corning, Inc.).
Alternatives: Mr. Frosty cooling container (Cat.#5100-0001, NALGENETM Cryo).
Preparation for preprocessing of fresh or cryopreserved FNA samples for single-cell droplet
generation
Timing: 20 min
5. Warm the water bath to 37C (needed to quickly thaw if FNA samples were cryopreserved)
STAR Protocols 2, 100581, June 18, 2021 ª 2021 The Authors.




6. Prepare cold PBS (Ca2+/Mg2+ free, Gibco, Cat.#10010-015) containing 0.04% BSA (filter steril-
ized), keep on ice
7. Label 5 mL Eppendorf’s (Eppendorf, Cat.#0030122313) or 15 mL centrifuge tubes (TPP,
Cat.#91015) with sample names/IDs
8. Prepare and label FACS tubes with blue filter cap (filter size 35 mM Cat.#352235, Falcon)
9. Prepare recommended medium for dead cell removal: PBS (Ca2+/Mg2+ free, Gibco,
Cat.#10010-015) with 1% FBS (Cat.#S006420E01, Biowest) and 1 mM CaCl2 (Cat.# 746495,
Sigma Aldrich) - for low viability samples
10. Prepare red blood cell lysis (Cat.#11814389001, ROCHE) for samples having red blood cells,
important to remove them from downstream single cell processing.
Optional: For convenience one may prepare a dry ice and keep the cryopreserved samples
nearby until ready for processing
KEY RESOURCES TABLE















Chemicals, peptides, and recombinant proteins
DMSO Sigma Cat.#102148154
FBS Biowest Cat.#S006420E01
BSA (bovine serum albumin) Sigma-Aldrich Cat.#A7906
CaCl2 Sigma Aldrich Cat.#746495
Critical commercial assays
Chromium Single Cell V(D)J









Logos Biosystems Inc. Cat.#L1001
PhotonSlides (ultra-low
fluorescence counting slides)
Logos Biosystems Inc. Cat.#L12005
Acridine orange propidium
iodide (AOPI) stain




Annexin Dead Cell Removal Kit STEMCELL
Technologies
Cat.#17899
Red Blood Cell Lysis Buffer Roche Cat.#11814389001
High Sensitivity DNA Kit Agilent Technologies Cat.#5067-4626
Agilent 2100 Bioanalyzer Agilent Technologies System no. G1030AX
Software and algorithms
ScanScope CS Aperio http://scanscope.com/
Seurat Satija Lab https://satijalab.org/seurat/index.html
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This section describes how to collect FNA samples from cutaneous cancers and cryopreserve using a
slow-freezing procedure, as well as preprocess the cryopreserved or freshly sampled FNA sample for
single cell RNA-seq processing and single-cell data analysis tools.
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
CellRanger 10x Genomics https://support.10xgenomics.com/
single-cell-gene-expression/software/
pipelines/latest/what-is-cell-ranger






(blue capped FACS tubes)
Falcon Cat.#352235
Eppendorf Tubes 5.0 mL
with Screw Cap
Eppendorf Cat.#0030122313




15 mL Centrifuge tubes TPP Cat.#91015
Steriflip, 0.22 mM filter Milipore Cat.#SCGP00525
Washing and resuspension buffer (PBS with 0.04% BSA )
Reagent Final concentration Amount
BSA 1% 20 mL
PBS (Ca2+/Mg2+ free) n/a 480 mL
Total n/a 500 mL
Prepare 1% BSA by dissolving 1 g of BSA (Cat.#A7906, Sigma-Aldrich) in 100 mL of sterile PBS (Ca2+/Mg2+ free, Gibco,
Cat.#10010-015) and filter through 0.22 mM filter (Steriflip, Milipore, Cat.#SCGP00525). Store for up to 1 month at 4C, check
for visible contaminations.
Recommended medium for dead cell removal
Reagent Final concentration Amount
FBS 2% 200 mL
CaCl2 1 mM 200 mL
PBS (Ca2+/Mg2+ free) n/a 9.6 mL
Total n/a 10 mL
Always prepare fresh and filter the final solution with 0.22 mM filter (Steriflip, Milipore, Cat.#SCGP00525).
Cryopreservation medium (also FNA collection medium)
Reagent Final concentration Amount
FCS 90% 900 mL
DMSO 10% 100 mL
Total n/a 1 mL
Per sample preparation, prepare fresh, filter the final solution with 0.22 mMfilter (Steriflip, Milipore Cat.#SCGP00525), store for
a short time, up to one week at 4C.
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FNA is a minimally invasive procedure that allows repetitive sample collection from the same lesion.
This enables the profiling of changes in cell composition over time, e.g., before and during the
therapy.
1. FNA procedure
a. Disinfect the surface of the lesion with ethanol pads
b. Fix the skin lesion between the thumb and index finger of the non-dominant hand to stabilize
and prevent slipping of the lesion and accidental pre-mature syringe withdrawal (Figure 1)
c. At the edge of the lesion, aiming toward the center, insert the needle on a syringe (empty)
fixed in the syringe holder (Pistomed) at approx. 90 angle in bigger tumors and ca 45 angle
in superficial lesions, such as plaques (Figure 1). In case of accidental piercing through the
lesion, pull the syringe back to keep the needle tip within the lesion proceed to the next step
d. Pull the plunger to apply negative pressure once the lesion is penetrated. If the lesion is
necrotic and you cannot create negative pressure, move the syringe within the lesion until it
reaches a solid part and you feel resistance (creation of negative pressure) while pulling the
plunger
e. To sample as many parts of the lesion as possible, move the syringe in and out within the lesion
in a fan-shaped manner for at least 10 times without taking the needle out of the lesion
f. Once tissue material (reddish or yellowish, depending on the tumor type and erythrocyte con-
tent) appears in the syringe hub, release the plunger to remove negative pressure and slowly
withdraw the needle from the lesion. If the syringe hub does not fill, move the syringe to other
areas of the lesion or troubleshoot for needle clogging (see below), if the whole lesion area
was penetrated
g. Put a bandage on the needle insertion site
2. Transferring the sample to the slow-freezing medium
a. Aspirate the slow freezingmedium to the syringe, which contains the collected sample and put
it back to the cryovial
b. Keep the needle in the fluid and move the plunger in and out of the syringe to suspend the
remaining cells in the syringe hub until most cells are transferred
c. Close the cryovial and keep it on ice until biobanking.
Alternatives: FNA samples can be processed fresh. When planning to process the samples
freshly without cryopreservation, collect the samples in 1 mL 100% FCS. After collection,
transfer into a 5 mL Eppendorf or 15 mL centrifuge tubes and top up with 4 mL or 9 mL of
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any medium (RPMI or DMEM), respectively. Keep on ice and process as soon as possible, we
have processed freshly collected FNAs within 2 h after collection.
FNA live-cell biobanking
Timing: 30 min
3. Keep the collected FNA sample on ice at all times. Place the cryovial with the FNA sample in pre-
chilled Corning CoolCell Containers (432001) and put into 80 fridges within 30 min after
collection.
4. Leave the Corning CoolCell Containers at 80 for at least 4 h and after the sample is fully
frozen, transfer the samples to liquid nitrogen for prolonged storage.
Pause point: After the FNA sample is cryopreserved, it could be stored until convenient for
processing. The samples could be stored in liquid nitrogen for at least 2 years. We recom-
mend collecting at least eight samples to process simultaneously.
Preprocessing FNA samples for single-cell droplet generation
Timing: 60–90 min
Within this step, a cryopreserved FNA sample is thawed, assessed for quality and preprocessed for
single cell droplet generation (Figure 2).
5. Thawing the frozen FNA sample (work in the BSL2 hood for human primary material). When pro-
cessing freshly collected FNA sample go directly to step 7.
a. Prepare a 5 mL Eppendorf or 15 mL centrifuge tube and put 1 mL of cold PBS (Ca2+/Mg2+ free)
with 0.04% BSA. A 5 mL Eppendorf allows better pellet visualization when the cellular content
in the sample is low.
b. Take frozen cryovials with FNA samples out of the freezer/dry icebox and submerge (not fully;
only until the cup line) into a water bath pre-warmed to 37C. Keep in the water bath until
almost thawed.When a small frozen part (around 20% of the total volume) is left, take the cryo-
vial with almost thawed FNA out, open, gently transfer the thawed FNA samples into a 5 mL
Eppendorf or 15 mL centrifuge tube, and slowly pipette up and down several times.
Figure 2. Preprocessing of freshly collected and live-cell biobanked FNA samples
Main steps and troubleshooting are outlined.
ll
OPEN ACCESS
STAR Protocols 2, 100581, June 18, 2021 5
Protocol
c. Add 1 mL of PBS with 0.04% BSA onto a remaining frozen FNA sample and pipette up and
down. This should melt what remains of the FNA sample.
d. Transfer the rest of the FNA sample into a 5 mL Eppendorf or 15 mL centrifuge tube and bring
the total volume to 10 mL with PBS with 0.04% BSA. Do not use big serological pipettes as this
might result in loss of the cells on the inner surface of the pipette.
e. Leave on ice for 10 min. This should allow the remaining DMSO to diffuse from the cells.
f. Spin down at 300 3 g for 5 min at 4C, remove the supernatant and re-suspend in 100–500 mL
of PBS with 0.04% BSA. The resuspension volume depends on the pellet size.
6. Counting cells and viability
a. Take an appropriate volume of the acridine orange propidium iodide stain (AOPI, e.g., Logos
Biosystems Inc., cat.#F23001) mix with cells, load on the counting slide (Photon slides, Ultra-
low fluorescence counting slides, cat.# L12005) and count on the available live/dead counting
machine (e.g., Luna-FLTM Dual Fluorescence Cell counter). E.g., To save cellular content we
used 5 mL of AOPI stain, 5 mL of single cell suspension, and set the cell counter to 1:2 dilution.
CRITICAL: We highly recommend using live-dead cell staining; our best practice was AOPI
as it allows quick viability and cell count determination. Check the sample images for
clumps and debris. At least one filtering step is needed to obtain a single cell suspension
free of debris. Sometimes it might improve the viability and cell number accuracy as the cell
counter might count debris as cells (See Figure 3 for optimal, suboptimal and dropout ex-
amples images).
Alternatives: e.g., Cellometer K2 Fluorescent (Nexcelom) or any cell counter that supports
AOPI dual-fluorescence imaging.
b. It is highly recommended to filter the cell suspension through a 35 mM cell strainer. E.g., FACS
tubes with blue filter caps. If debris and clumps are present (see Figure 3C, FNA_Sample3 for
debris and fibers present in single cell suspension), more than one filtering step might be
required to achieve a fine single cell suspension.
CRITICAL: Wash the filter cap with 23 mL of PBS to reduce cell loss during the filtering
step. Usually 10–30% of cell loss is expected.
c. Transfer the filtered cell suspension into a new 5 mL Eppendorf tube (to reduce carryover of
debris and fibers) and spin down at 300 3 g for 5 min at 4C.
d. Resuspend cells in 50–500 mL of PBS with 0.04% BSA and count with AOPI live/dead staining.
For single cell droplet generation the cell concentration was brought to 700–1200 cells/mL.
Good example shown in Figure 3A, FNA_Sample1, good cell concentration, good viability,
clear single cell suspension.
7. Processing cells for single cell droplet generation and sequencing library construction should be
done according to the 103 protocol for Chromium Next GEM Single Cell 3ʹ Reagent Kits v3.1 or
Chromium Single Cell V(D)J Reagent Kits User Guide.
Pause point: After the single cell droplet generation, the sample is processed for a reverse
transcription reaction according to the 103Genomics protocol and could be stored for 72 h at
4C. See the 103 Genomics protocol for more possible pause points.
Optional steps:
a. Dead cell removal: If the viability is below 50% and cell number allows (>0.53 105), we recom-
mend performing dead cell removal, following manufacturer instructions, using the EasySep
Dead Cell Removal (Annexin V) kit (StemCell Technologies, Cat#17899) and EasySepTM Mag-
net (StemCell Technologies, cat. #18000) designed to deplete apoptotic (Annexin V+) cells by
ll
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immunomagnetic negative selection. Manufacturer instructions: https://cdn.stemcell.com/
media/files/pis/DX21956-PIS_1_0_1.pdf?_ga=2.34218465.1547447083.1547219505%E2%
80%93776976877.1534951026. To avoid complete loss of sample, we recommend putting
aside 104 cells and performing dead cell removal on the rest of the sample.
b. Slow spin to remove dead cells and cell debris: If cell number is below 0.53 105 a slow spin at
2503 g for 10 min could be performed to increase the viability. After the slow spin, it is impor-
tant to check for cell pellet presence before discarding the supernatant.
c. Red blood cell lysis: When the pellet appears red, a simple quick red blood lysis step could be
performed using a red blood cell lysis buffer (RBCL, ROCHE, cat.#11814389001). Spin down
the cell suspension at 300 3 g for 5 min. Resuspend in 500 mL of RBCL buffer and shake at
around 22C for 3–5 min. Top up with PBS with 0.04% BSA (to 5 mL in 5 mL Eppendorf or
10 mL in 15 mL centrifuge tubes) and spin down at 3003 g for 5 min. If the pellet still appears
red, repeat the step up to 3 times.
EXPECTED OUTCOMES
With the FNA procedure, we typically obtained minimum 7000 cells, maximum 0.5 3 106 cells, with
average of 53 104 cells. The FNAmaterial that we processed for single cell sequencing was between
50%–80% and we used dead cell removal (optional step a) or slow spinning (optional step b) to
Figure 3. Examples of the good, suboptimal quality and clear dropouts from fine needle aspirate samples during
preprocessing prior to single cell droplet generation
(A) FNA_Sample1 – Good quality sample, good cell concentration, good viability, clear single cell suspension. Total
cell concentration: 3.78 3 106 cells/mL; Live cell concentration: 3.10 3 106 cells/mL; Dead cell concentration: 6.76 3
105 cells/mL; Viability: 82.1%.
(B) FNA_Sample2 – Suboptimal sample: good cell concentration, but poor viability, clear single cell suspension. Total
cell concentration: 1.07 3 106 cells/mL; Live cell concentration: 5.55 3 105 cells/mL; Dead cell concentration: 5.11 3
105 cells/mL; Viability: 52.1%.
(C) FNA_Sample3 – Suboptimal sample: acceptable cell concentration, good viability, visible fibers and cell clumps in
single cell suspension. Total cell concentration: 4.15 3 105 cells/mL; Live cell concentration: 3.42 3 105 cells/mL; Dead
cell concentration: 7.24 3 104 cells/mL; Viability: 82.5%.
(D) FNA_Sample4 – Clear drop out: low cell concentration, poor viability. Total cell concentration: 2.01 3 105 cells/mL;
Live cell concentration: 4.02 3 104 cells/mL; Dead cell concentration: 1.61 3 105 cells/mL; Viability: 20.0%. All image
magnifications: 1.43, taken by Luna cell counter. Labeled in green alive cells, in red dead cells.
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increase the viability when below 70%. Please see Figure 3 for optimal and suboptimal sample qual-
ity examples.
QUANTIFICATION AND STATISTICAL ANALYSIS
 Preprocessing
We recommend using the 10X cellranger (https://support.10xgenomics.com/single-cell-vdj/
software/downloads/latest) pipeline for processing the data. The software takes raw
sequencing files as input and tags the reads according to barcodes and indices. The command
‘cellranger count’ generates a cell-gene count matrix, whereas the command ‘cellranger vdj’
assembles immune receptor contigs and annotates them.
 Quality control
The cellranger pipeline also outputs a summary HTML file that should be inspected before
proceeding with the downstream analysis. The report may implicate concerns with the library
preparation or with the sample quality. This report can be used as a feedback to optimize the
library preparation to achieve the desired sequencing depth.
 Downstream analysis
a. The downstream analysis of the samples may vary greatly depending on the setup of the exper-
iment. In the following, we describe procedures that we view as essential when working with
such data. For more details and the related code, we refer to the following GitHub page:
https://github.com/uzh-dqbm-cmi/lymphoma_tvec_study .
b. The ‘cellranger count’ command outputs filtered count matrices in files named barco-
des.tsv.gz, features.tsv.gz, matrix.mtx.gz. These files can be read, using the Seurat R package
(Butler et al., 2018). This package can be used to filter cells (e.g., by read count, gene count or
mitochondrial read ratio), to perform differential gene expression and to visualize the results.
c. For cell-typing, we recommend using the SingleR R package (Aran et al., 2019).
d. From the outputs of the ‘cellranger vdj’ command, the filtered_contig_annotations.csv file con-
tains the annotated immune receptor contigs. This file can be merged with the metadata data-
frame of the Seurat object to integrate gene expression analysis with immune receptor
profiling.
e. For gene set enrichment and pathway analysis, we recommend using the ClusterProfiler R
package (Yu et al., 2012).
TROUBLESHOOTING
Problem
If the syringe hub does not fill up during the FNA procedure (steps 1d–f)
Potential solution
Inspect the needle for a clog and repeat the process.
Problem
If a syringe was accidentally withdrawn from the lesion before the syringe hub fills with tissuematerial
(steps 1c–e).
Potential solution
Carefully remove the needle from the lesion, release the air from the syringe, and restart the FNA
procedure after reattaching the needle.
Problem
If the lesion appears flat (step 1e)
ll
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Potential solution
In flat lesions, the moving of the syringe must usually be repeated more times before tissue material
appears in the syringe hub, compared to thicker or nodular lesions.
Problem
If tissue is not visible in the syringe hub (step 1)
Potential solution
If the content of syringe hub is difficult to assess for tissue material, after releasing the content into a
vial/cryovial, a drop of material can be taken for visual inspection under the microscope. Minimum
viable cell number that we recovered from FNA was around 7 3 103 cells per FNA, which was rather
on a low end.
Problem
Low cell concentration, total cell number less than 104 cells are recovered (step 6)
Potential solution
Spin down the cell suspension at 3503 g for 5 min at 4C, remove the excess supernatant and leave
around 15 mL of resuspension buffer to achieve a minimum concentration of 700 cells/mL.
Problem
Suboptimal viability (less than 60%) and the cell number is less than 105 (step 6, Figure 3B)
Potential solution
Try to perform slow spin at 250 3 g for 10 min. Warning: Might result in a drop out or suboptimal
quality data after at the data analysis step.
Problem
Cell number is more than 5 3 104, good viability (more than 80%), but cell suspencion has visible
fibers and cell clumps (step 6, Figure 3C).
Potential solution
Perform additional filtering steps using 35–40 mM cell strainers to remove fibers. If debris and fibers
are not removed might result in clogging during single cell droplet generation.
Problem
The sample has a high median read/cell ratio with a low cell count or a substantially lower cell count
than expected (see Downstream analysis).
Potential Solution
The problem is likely due to the low sample quality or with themicrofluidics process. Presumably, too
few surviving cells were loaded to the microfluidics device. If some samples have very different cov-
erages that likely leads to batch effects in the downstream analysis. It is recommended to repeat the
protocol from the ‘‘Preparation of FNA sample for single cell processing’’ chapter. Additional exam-
ples that resulted in drop out at the data analysis step and would need to be re-processed are listed
in Table 1.
Problem
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Potential Solution
This can be a consequence of merging another dataframe with the metadata dataframe. The Seurat
object usually stores the count matrices sorted alphabetically. Sorting the rows of the metadata da-
taframe by the cell identifiers is likely to solve the problem.
LIMITATIONS
Main limitations for FNA sampling and pre-processing for single cell analysis are necrotic or flat le-
sions, as cell number and the cell viability obtained from such lesions often result in drop-outs. We
have observed suboptimal sampleswith low cell concentrations, low total numbers, andpoor viability
(Figure 3D); therefore, we would recommend bringing the viability of cells whenever possible to at
least to 70% and concentrating cells to minimum of 700 cells/mL for single cell droplet generation.
Lower concentrated cells and viabilities resulted in drop-outs or issues at the data analysis step.
RESOURCE AVAILABILITY
Lead contact
Further information and requests for resources and reagents should be directed to and will be ful-
filled by the lead contact, Prof. Mitch Levesque mitchell.levesque@usz.ch
Table 1. Summary of drop-outs and samples with suboptimal quality at data analysis step, AOPI - acridine orange propidium iodide; QC - quality
control; BCR - B-cell receptor; TCR - T-cell receptor.
Description of a
problem at the data




and interpretation Cause of the problem
Samples that were
classified as clear drop-
outs
Drop-out Sample 1 no AOPI QC of cells (as
described in step 7 of
the protocol)
Number of Cells: 93
Reads per cell: 809,921
Genes per cell: 66





Drop-out Sample 2 no AOPI QC of cells (as
described in step 7 of
the protocol)
Number of cells: 6,326
Reads per cell: 26,021
Genes per cell: 526
Low fraction of reads in





Drop-out Sample 3 Viability 53.4%
Total cell number
~1000 cells
Number of Cells: 64
Reads per Cell:
403,052
Genes per Cell: 72
Low cell number, few
genes per cell
Low viability





Drop-out Sample 5 Viability 66.4% BCR analysis: Cells with
productive V-J
spanning pair: 1,663
B-cells in sample: 833
TCR analysis: Cells with
productive V-J
spanning pair: 852
T-cells in the sample:
243
More BCRs and TCRs







Drop-out Sample 6 Viability 40.4% BCR analysis: Cells with
productive V-J
spanning pair: 393
B-cells in sample: 773
TCR analysis: Cells with
productive V-J
spanning pair: 144
T-cells in the sample:
1,853
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Materials availability
No new material was generated using this protocol.
Data and code availability
The code used for the analysis of scRNA sequencing data can be found online at https://github.com/
uzh-dqbm-cmi/lymphoma_tvec_study .
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